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Abstract 
The concentration of CD4+ T-lymphocytes (CD4 count) in a person’s plasma is widely used to decide when to start HIV-
positive people on anti-retroviral therapy (ART) and to predict the impact of ART on the future course of HIV and 
tuberculosis (TB). However, CD4+ cell-counts vary widely within and among populations and depend on many factors 
besides HIV-infection. The way in which CD4 counts decline over the course of HIV infection is neither well understood 
nor widely agreed. We review what is known about CD4 counts in relation to HIV and TB and discuss areas in which 
more research is needed to build a consensus on how to interpret and use CD4 counts in clinical practice and to develop a 
better understanding of the dynamics and control of HIV and HIV-related TB. 
 
Introduction 
CD4+ T-lymphocytes (CD4 cells) play a key role in HIV-
infection. HIV uses CD4 cells to replicate and resting CD4 
cells can continue to harbour the virus even with effective 
ART.1,2 During the acute phase of infection the virus 
infects CD4 cells, viraemia increases exponentially to very 
high levels and the concentration of CD4 cells in the 
plasma (CD4 count) drops by about 25%. After about one 
month cytotoxic T-cells control the primary infection, 
viraemia falls and CD4 counts recover. During the chronic 
phase of infection, which can last from about 2 to 20 years, 
the virus replicates in the peripheral lymphatic tissue and 
CD4 counts decline slowly3-7 eventually to zero, but with 
increasing mortality8 and incidence of opportunistic 
infections,9 including tuberculosis.7,10,11 The rate at which 
CD4 counts decline is determined by the rate of permanent 
viral replication. Once HIV-positive people start anti-
retroviral therapy (ART), CD4 counts increase12 and 
overall mortality13 and the incidence of TB14 decline.  
 Because of their association with disease progression, 
CD4 counts are used as a prognostic marker for deciding 
when to start treatment.15-24 They have also been used to 
model the impact of starting ART at different CD4 
counts25-27 and for predicting the impact of ART on TB.7,10 
 The recommended CD4 count threshold, below which 
people should start ART, has varied greatly over the 
years,28 and the recommendations have sometimes 
included a viral load threshold. The CD4 count thresholds 
are generally set at 200/µL, 350/µL, or 500/µL for no 
apparent reason25-27 and do not take into account the 
substantial variation within and among populations. Here 
we argue for the need to develop a better understanding of 
the in-host dynamics of CD4 counts and the implications 
that this has for the management of HIV in individuals and 
the control of HIV in populations. 
Observations 
HIV drives TB 
The most common opportunistic infection associated with 
HIV is TB and, especially in East and southern Africa, the 
epidemic of HIV has driven up the incidence of TB. As 
illustrated in Figure 1 the epidemic of HIV in Kisumu, 
Kenya started in the early 1980s and reached half of its 
peak value in 2000; the epidemic of TB followed with a 
delay of 5 years.29 When the epidemic of HIV stabilized 
the incidence of TB had increased by 11 times.  
 
 
 
 
 
 
 
 
 
 
Figure 1. Epidemic trends for HIV and TB in Kisumu, 
Kenya. Blue: adult prevalence of HIV; Red: TB 
notifications.29 
The incidence rate ratio 
In order to understand the impact of HIV on TB we need 
to know the TB incidence rate ratio, IRR, which is the 
relative risk of TB in HIV-positive and HIV-negative 
people. The first and the most direct demonstration of the 
IRR was published by Corbett et al.30 using data from gold 
miners in South Africa. In 1990 the prevalence of HIV 
among South African women attending public antenatal 
clinics (ANC) was 0.5%, by the year 2000 it had reached 
24%.31 During this time the IRR increased from 2 to 10 as 
shown in Figure 2. Of equal importance was the 
observation that the incidence of TB in HIV-negative 
mineworkers remained unchanged over the same period. 
 Other things being equal, the risk of TB infection is 
proportional to PTB, the prevalence of people with active 
TB disease. As a first approximation PTB is equal to the 
incidence, ITB, times the disease duration, DTB, so that 
 TB TB TBP I D= ! . 1 
Now consider the period from 1991 to 1999 as shown in 
Figure 2. Since the incidence of TB in HIV-negative 
people did not change and we can assume that the disease 
duration in HIV-negative people did not change we can 
 2 
conclude that the overall prevalence of TB did not change. 
However the incidence of TB in HIV-positive people did 
increase significantly and to maintain the same risk of 
infection in HIV-negative people, and therefore the same 
prevalence, there must have been a corresponding decrease 
in the disease duration in HIV-positive people.  
 
 
 
 
 
 
 
 
Figure 2. The incidence of TB among gold miners in 
South Africa between 1991 and 1999. Green: HIV-
negative; red: HIV-positive.30  
 The average TB disease duration in HIV-negative 
people is 1 to 2 years32 so that the disease duration in HIV-
positive people, without anti-retroviral treatment, must be 
1 to 2 months. From this it follows that even during a 
severe epidemic of HIV, conventional TB control should 
continue to work equally well for HIV-negative people. 
Since TB disease progresses so rapidly in HIV-positive 
people it will be very difficult to find HIV-positive people 
with active TB before they die. The control of HIV-related 
TB therefore depends largely on controlling HIV and 
ideally finding people with HIV and starting them on ART 
before they develop TB. 
 
 
 
 
 
 
 
 
 
 
Figure 3. The epidemics of HIV and TB in A: Zimbabwe 
and B: Botswana. The IRR in Zimbabwe is 34 and in 
Botswana is 7.4. 
Variations in the incidence rate ratio 
Direct data on the IRR are hard to obtain and the Corbett 
study30 is exceptional. However, we can estimate the IRR 
indirectly from time trends in the incidence of TB and the 
prevalence of HIV. Figure 3 shows data for Zimbabwe and 
Botswana.10 While the HIV-epidemics, at least up to the 
peak, are similar in the two countries, there are three 
important points to be made. First, before the epidemic of 
HIV started, the incidence of TB in Zimbabwe was about 
five times lower than in Botswana. Second, the absolute 
increase, after the HIV epidemic peaked, was about 350 
cases per 100k per year in both countries. Third the 
proportional increase in the incidence of TB in Zimbabwe 
was about three times greater than in Botswana. 
 To estimate the incidence rate ratio from the data in 
Figure 3 we let ITB be the incidence of TB, TBI+  and TBI!  
in HIV positive and negative people, respectively, and 
PHIV be the prevalence of HIV.† Then 
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where R = ITB/ TBI!  is the ratio of the TB incidence at a 
later time to the incidence before the HIV epidemic 
started.‡ From Equation 3 and the data in Figure 3, the IRR 
in Zimbabwe is 34, almost five times higher than in 
Botswana where it is 7.4. We consider possible 
explanations below. 
 
 
 
 
 
 
 
 
 
Figure 4. TB incidence as a function of CD4 counts in 
HIV-positive people from studies in public hospitals in 
Italy33 and in Cape Town.34 For every CD4 count drop 
of 100 cells/µL the incidence of TB increases by 62%. 
Correlates of TB incidence 
CD4 counts 
CD4 counts are significantly correlated with the incidence 
of TB in HIV-positive people (Figure 4). While correlation 
does not imply causation, the linear decline of CD4 counts 
after infection with HIV35 will lead to an exponential rise 
in the incidence of TB,33,36 people with advanced HIV 
infection will be more likely to develop TB, and this can 
account for the five year delay in the rise of TB.10 
Furthermore, this provides an explanation for the 
observation that the average value of the CD4 count in 
HIV-positive people presenting with TB is about 200/µL.7 
 An association with CD4 counts can also explain the 
3.8 (1.6!15.2) fold increase in the incidence of TB during 
the acute phase of HIV-infection.33 During the acute phase 
CD4 counts fall by about 25% (9%!41%).10,35 If we 
assume that the CD4 count in HIV-negative people is 
about 1,000 cells/µL then a drop of 250 cells/µL would 
increase the incidence of TB by a factor of about 3.  
                                                            
†  This result refers to an average over all HIV positive people in 
different stages of disease progression at a given time. 
‡  The incidence rate ratio can also be calculated from the prevalence of 
HIV in TB patients and the general population.61 
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Obesity 
There is a remarkably strong log-linear relationship 
between the incidence of TB and body mass index (BMI) 
in HIV negative people; the incidence of TB falls by 
13.8% (± 0.4%) across four orders of magnitude in the 
incidence of TB and BMI values ranging from 17 to 
32kg/m2, and in subjects ranging from residents of Hong 
Kong pensioners, to Finish smokers and US Navy 
recruits.37 
 
 
 
 
 
 
 
 
 
Figure 5. Log-linear relationship between BMI and the 
incidence of TB across nearly four orders of magnitude 
and BMI ranging from 17 to 32kg/m2. The incidence of 
TB falls by 13.8% (±0.4%) per unit increase in BMI.37 
Black: Hong Kong health centres for the elderly;38 
purple: male smokers in a Finnish cancer trial;39 red: US 
Navy recruits;40 green, NHANES, USA (P. Cegielski, 
pers. comm.); blue, US Navy recruits;41 brown: Mass 
Radiography Survey, Norway42 (p = 10!51). 
 Since HIV is a wasting disease it is possible that the 
association between CD4 counts and the incidence of TB 
is partly dependent on a progressive decline in BMI with 
time since HIV infection so that BMI could confound the 
apparent relationship between CD4 counts and TB. To 
achieve a three fold increase in TB as a result of a decline 
in BMI, people would have to lose about 8 kg/m2 of BMI 
during the acute phase; to bring about a ten-fold increase 
in the incidence of TB in people with an established HIV 
infection they would have to lose about 16 kg/m2 of BMI 
neither of which seem plausible. While few studies seem 
to have collected time series data on BMI over the course 
of an HIV-infection at least one study suggests that BMI 
only falls significantly during the last six months before 
the onset of AIDS.43 One of the few studies on BMI and 
CD4 counts44 suggests that increasing BMI is associated 
with increasing CD4 cell counts but the effect would only 
explain a small part of the decrease in TB with increasing 
CD4 cell counts. In spite of the very strong association 
between BMI and TB this seems unlikely to confound the 
relationship between CD4 counts and TB. 
CD4 count variation among populations 
CD4 count distributions vary widely among different 
populations.35 As shown in Figure 6 four studies in HIV-
negative people in Ethiopia45,46 (red 1) consistently give 
mean values of about 750/µL with a 95% range of about 
±200/µL. However the CD4 counts vary greatly both in 
their ranges, from ±90/µL in Tanzania47,48 to ±530/µL in 
Botswana49 (blue 2), and in their means, from 1,150/µL50 
in Uganda to 591/µL in Botswana49 (green 3). 
 CD4 cell counts are highly variable among and within 
individuals depending on their sex, stress levels, fitness 
levels, time of day, pregnancy, age and many other 
things.51 If CD4 counts are to help us to understand the 
dynamics of HIV infection and the incidence of 
opportunistic infections as well as to provide a useful 
prognostic marker, all of this variation needs to be allowed 
for and, if possible, understood. 
 
 
 
 
 
 
 
 
 
 
Figure 6. CD4 count variability in HIV negative 
populations. The central ellipses indicate 95% confidence 
limits on the estimated mean values and the points at the 
end of each line indicate 95% estimates of the population 
distribution. Circled numbers are discussed in the text. 
Modelling CD4 count progression 
In order to understand the relationship between CD4 
counts and disease progression, individual prognosis and 
the incidence of opportunistic infections, it will be 
necessary to model the in-host dynamics of CD4 counts in 
relation to HIV infection. First, this must include the 
variation in CD4 counts within a given population (Figure 
6). Second it must include the variation in the mean and 
the spread of CD4 counts among populations (Figure 6). 
Third, it must include the variation in survival in people 
infected with HIV which ranges from 2 year to 20 years.52 
Fourth, it must allow for the age of the infected person 
since the median survival after infection with HIV varies 
from 16 years in those infected (horizontally) before the 
age of 5 years to 4 years in those infected after the age of 
65 years.52 Fifth, it must allow for the state of the 
epidemic; when the prevalence is rising people are more 
likely to have been infected recently and when it is falling 
they are less likely to have been infected recently. 
 A simple phenomenological model was developed to 
allow for the variation in initial CD4 counts and survival, 
taking into account the distribution of CD4 counts in the 
relevant population, and assuming that survival is 
independent of the initial CD4 count.35 With this model it 
has been possible to predict the CD4 count distribution in 
HIV-positive people from the distribution in HIV-negative 
people,35 the variability in the rate of decline of CD4 
counts,53 and the one-year mortality of post-partum 
women,8 in all cases with no free parameters apart from a 
normalization factor. The assumption of a linear decline in 
CD4 counts with time since infection is consistent with at 
least one detailed model of the immune response to HIV54 
but much further work is needed in this regard. 
CD4 recovery under ART 
Modern anti-retroviral therapy can suppress viral load in 
people infected with HIV by up to 10 thousand times55-57 
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and this can be sustained for at least seven years55,56 and 
probably indefinitely. It also leads to significant increases 
in CD4 counts as shown in Figure 7. 
 What is remarkable about the data in Figure 7 is the 
consistency of the rate of increase and the asymptotic 
values with the only difference being the CD4 count at the 
start of treatment. Given the great variability in CD4 cell 
counts in HIV-negative people this consistency in the 
recovery rates in HIV-positive people is unexpected. The 
CD4 counts all converge exponentially at a rate of 
224/µL/year (±35/µL/yr) to an asymptote that is 371/µL 
(±16/µL) above the value at the start of treatment. This 
suggests that if ART is started late, the infected person’s 
immune function will never fully recover. It would be of 
interest to develop a simple model of CD4 cell recovery 
under ART that can help to explain the data in Figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 A. CD4 count recovery under ART. The fitted 
lines differ only in their initial starting points and have 
the same rate of increase and the same asymptote. B. 
The fitted curve and confidence bands with data offset to 
their initial values. Asymptote: 371 (355!389)/µL; rate 
of increase: 224 (192!261)/µL. Data from Gras et al.58 
but see also De Beaudrap et al.59 
 There is good data to suggest that the ‘recovery’ of the 
immune system with respect to TB is never complete as 
shown in Figure 8 where even those people whose CD4 
count rose to 800/µL still suffered a TB incidence about 4 
times the rate in HIV-negative people. 
 Several studies have shown that ART reduces the 
incidence of TB by about 60% irrespective of the CD4 
count at which treatment starts.10,60 This apparent 
consistency in the proportional decline in the incidence of 
TB is consistent with the observation that the increase in 
CD4 counts after the start of ART is independent of the 
CD4 counts at the start of treatment (Figure 7) and that the 
incidence of TB varies exponentially with the change in 
CD4 counts (Figure 4). In the studies showing a consistent 
decrease in TB incidence the mean duration of follow up 
was between 1 and 2 years during which time the increase 
in CD4 counts must have been between 200 and 250 
cells/µL. The estimate in Figure 4 of a 62% increase in TB 
for every 100 cells/µL decline in CD4 counts would 
suggest that ART should reduce the incidence of TB after 
1 to 2 years by between 70% and 80%, similar to the 60% 
decline noted above. 
 
 
 
 
 
 
 
 
 
 
Figure 8. Decline in the incidence of TB among people 
on ART as a function of CD4 count. Brown point: HIV-
negative people in the same community.14 
Incidence rate ratios revisited 
Two explanations have been proffered for the variability in 
the IRR. The first follows from the fact that we are 
comparing the prevalence of HIV with the incidence of TB 
so that clustering of the two infections in the same sub-
populations could produce the observed effect. For 
example, suppose that the incidence of TB in those 
infected with HIV increased by a fixed factor. Then if one 
added to the population an equal number of people without 
TB or HIV the prevalence of HIV would be halved, the 
incidence of TB per person would also be halved, before 
and after the introduction of HIV, but the proportional 
increase in TB would remain the same and the IRR would 
appear to have doubled. This argument is supported by the 
observation that in concentrated epidemics in developed 
countries the IRR appears to be about 60, very much 
higher than in generalized epidemics in most developing 
countries.61 The putative explanation for this is that in 
developed countries the same subset of often marginalized 
people is at high risk of both HIV and TB. An alternative 
explanation is that in countries like Botswana where the 
CD4 counts in HIV-negative people are very low they are 
more susceptible to developing TB when they are HIV-
negative while in Zimbabwe, where the CD4 count in 
HIV-negative people is much higher, they are less 
susceptible to developing TB when they are HIV-negative. 
But because people in Botswana start with a low CD4 
count while people in Zimbabwe start with a high CD4 
count, the CD4 decline in Zimbabwe is greater than in 
Botswana and the increase in TB is correspondingly 
greater in Zimbabwe.  
Discussion 
What do we know? 
Certain aspects of the HIV-TB epidemic are clear: the 
epidemic of HIV drives up the incidence of TB with a 
delay of about 5 years; the incidence rate ratio is 
substantial but varies among African populations from 
about 5 to about 20; HIV does not appear to increase the 
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prevalence of TB; ART reduces the incidence of TB but 
only by about 60% and apparently by the same amount at 
all CD4 counts. CD4 counts vary greatly both within and 
among populations and even within individuals over time. 
What do we understand? 
HIV does not affect the incidence of TB in HIV negative 
people, and therefore the overall prevalence of TB, 
because the increase in the incidence of disease is balanced 
by a decrease in the duration of disease and to some extent 
by the fact that HIV-positive people are more likely to 
develop disseminated TB and therefore to be less 
infectious than HIV-negative people.  
What can we tentatively conclude? 
Conventional TB control among HIV-negative people 
should work equally well in the face of an epidemic of 
HIV. CD4 counts may provide the link between HIV and 
the increasing incidence of TB but this is hard to establish 
definitively. Since the rate and extent of CD4 recovery is 
independent of the CD4 count at the start of ART the 
proportional reduction in the incidence of TB is 
independent of the CD4 count at the start of treatment and 
is never complete. 
What do we still not understand? 
Given that CD4 cell counts are so variable and the fact that 
HIV relies on CD4 cells to replicate, what are the 
consequences of this for the progression of HIV infection 
in individual people? Are the CD4 counts in the peripheral 
lymphatic tissue relatively constant even though the CD4 
counts in the plasma fall over the course of infection? Why 
does it appear to be the case that survival is independent of 
the CD4 cell count before infection? If CD4 counts are 
predictive of the risk of TB in HIV-positive people, is this 
also true in HIV negative people? Since the decline in 
CD4 cell counts is so variable when people are infected 
with HIV, why is the recovery so consistent? Why does 
the incidence rate ratio vary by a factor of up to 5 among 
different but seemingly similar populations and epidemics 
of HIV? Do CD4 cell counts have any prognostic value for 
individual patients? Can we realistically model the 
immune response to TB and learn important lessons about 
how to control TB in the presence of HIV? 
References 
1. Stilianakis NI, Schenzle D. On the intra-host dynamics of HIV-1 
infections. Math. Biosci. 2006; 199: 1-25. 
2. Haase AT. Population biology of HIV-1 infection: viral and CD4+ 
T cell demographics and dynamics in lymphatic tissues. Ann. Rev. 
Immunol. 1999; 17: 625-56. 
3. Katubulushi M, Zulu I, Yavwa F, Kelly P. Slow decline in CD4 cell 
count in a cohort of HIV-infected adults living in Lusaka, Zambia. 
AIDS. 2005; 19: 102-3. 
4. Detels R, English PA, Giorgi JV, Visscher BR, Fahey JL, Taylor 
JM, et al. Patterns of CD4+ cell changes after HIV-1 infection 
indicate the existence of a codeterminant of AIDS. JAIDS. 1988; 1: 
390-5. 
5. Lang W, Perkins H, Anderson RE, Royce R, Jewell N, Winkelstein 
W, Jr. Patterns of T lymphocyte changes with human 
immunodeficiency virus infection: from seroconversion to the 
development of AIDS. JAIDS. 1989; 2: 63-9. 
6. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo 
CR, et al. Natural history of human immunodeficiency virus type 1 
viremia after seroconversion and proximal to AIDS in a large cohort 
of homosexual men. Multicenter AIDS Cohort Study. J. Infect. Dis. 
2000; 181: 872-80. 
7. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in 
the era of HIV/AIDS. Science. 2003; 301: 1535-7. 
8. Williams BG, Hargrove JW, Humphrey JH. The benefits of early 
treatment for HIV. AIDS. 2010; 24: 1790-1. 
9. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, 
Seage GR, et al. The cost effectiveness of combination antiretroviral 
therapy for HIV disease. N. Engl. J. Med. 2001; 344: 824-31. 
10. Williams BG, Granich R, De Cock K, Glaziou P, Sharma A, Dye C. 
Anti-retroviral therapy for the control of HIV-associated 
tuberculosis: modelling the potential effects in nine African 
countries. Proc. Nat. Acad. Sc. USA. 2010; 107: 17853-4. 
11. Williams BG, Granich R, Chauhan LS, Dharmshaktu NS, Dye C. 
The impact of HIV/AIDS on the control of tuberculosis in India. 
Proc. Nat. Acad. Sc. USA. 2005; 102: 9619-24. 
12. Gras L, Kesselring AM, Griffin JT, van Sighem AI, Fraser C, Ghani 
AC, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years 
of highly active antiretroviral therapy are feasible in most patients 
starting with 350 cells/mm3 or greater. JAIDS. 2007; 45: 183-92. 
13. Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, 
et al. Routine versus clinically driven laboratory monitoring of HIV 
antiretroviral therapy in Africa (DART): a randomised non-
inferiority trial. Lancet. 2010; 375: 123-31. 
14. Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Tuberculosis 
incidence rates during 8 years of follow-up of an antiretroviral 
treatment cohort in South Africa: comparison with rates in the 
community. PLoS ONE. 2012; 7: e34156. 
15. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, 
Jacobsen DM, et al. Treatment for adult HIV infection: 2006 
recommendations of the International AIDS Society-USA panel. 
JAMA. 2006; 296: 827-43. 
16. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, 
Carpenter CC, et al. Treatment for adult HIV infection: 2004 
recommendations of the International AIDS Society-USA Panel. 
JAMA. 2004; 292: 251-65. 
17. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, 
Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 
2002: updated recommendations of the International AIDS Society-
USA Panel. JAMA. 2002; 288: 222-35. 
18. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, 
Hammer SM, et al. Antiretroviral therapy in adults: updated 
recommendations of the International AIDS Society-USA Panel. 
JAMA. 2000; 283: 381-90. 
19. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, 
Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 
1998: updated recommendations of the International AIDS Society-
USA Panel. JAMA. 1998; 280: 78-86. 
20. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, 
Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 
1997. Updated recommendations of the International AIDS Society-
USA panel. JAMA. 1997; 277: 1962-9. 
21. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, 
Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 
1996. Recommendations of an international panel. International 
AIDS Society-USA. JAMA. 1996; 276: 146-54. 
22. WHO 2007. Antiretroviral therapy for HIV infection in adults and 
adolescents:  Recommendations  for a public health approach  2006 
revision. Geneva: WHO/UNAIDS. 
23. WHO 2003. Scaling up antiretroviral therapy in resource-limited 
settings: Treatment guidelines for a public health approach. Geneva: 
World Health Organization. 
24. WHO 2003. Treatment of tuberculosis: guidelines for national 
programmes. WHO/CDS/TB/2003.313. Geneva: World Health 
Organization. 
25. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. 
Universal voluntary HIV testing with immediate antiretroviral 
therapy as a strategy for elimination of HIV transmission: a 
mathematical model. Lancet. 2008; 373: 48-57. 
 6 
26. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. 
The case for expanding access to highly active antiretroviral therapy 
to curb the growth of the HIV epidemic. Lancet. 2006; 368: 531-6. 
27. Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, 
Bershteyn A, et al. HIV Treatment as Prevention: Systematic 
Comparison of Mathematical Models of the Potential Impact of 
Antiretroviral Therapy on HIV Incidence in South Africa. PLoS 
Med. 2012; 9: e1001245. 
28. Williams BG, van Rooyen R, Nieuwoudt M. Anti-retroviral therapy 
for HIV: who should we test and who should we treat? arXiv  2012; 
Available from: http://arxiv.org/abs/1208.3434 
29. Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. 
Tuberculosis control in the era of HIV. Nature Reviews of 
Immunology. 2005; 5: 819-26. 
30. Corbett EL, Charalambous S, Fielding K, Clayton T, Hayes RJ, De 
Cock KM, et al. Stable incidence rates of tuberculosis (TB) among 
human immunodeficiency virus (HIV)-negative South African gold 
miners during a decade of epidemic HIV-associated TB. J. Infect. 
Dis. 2003; 188: 1156-63. 
31. Williams BG, Gouws E. The epidemiology of human 
immunodeficiency virus in South Africa. Philos. Trans. R. Soc. 
Lond. B. Biol. Sci. 2001; 356: 1077-86. 
32. Bacaer N, Ouifki R, Pretorius C, Wood R, Williams BG. Modeling 
the joint epidemics of TB and HIV in a South African township. J. 
Math. Biol. 2008; 57: 557-93. 
33. Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for 
tuberculosis in HIV-infected persons. A prospective cohort study. 
The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). 
JAMA. 1995; 274: 143-8. 
34. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in 
people infected with HIV-1 before antiretroviral therapy in South 
Africa: a longitudinal study. Lancet. 2006; 368: 1254-9. 
35. Williams BG, Korenromp EL, Gouws E, Schmid GP, Auvert B, 
Dye C. HIV Infection, antiretroviral therapy, and CD4+ cell count 
distributions in African populations. J. Infect. Dis. 2006; 194: 1450-
8. 
36. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral 
therapy on incidence of tuberculosis in South Africa: a cohort study. 
Lancet. 2002; 359: 2059-64. 
37. Lonnroth K, Williams BG, Cegielski P, Dye C. A consistent log-
linear relationship between tuberculosis incidence and body mass 
index. Int. J. Epidemiol. 2010; 39: 149-55. 
38. Leung CC, Lam TH, Chan WM, Yew WW, Ho KS, Leung G, et al. 
Lower risk of tuberculosis in obesity. Arch. Intern. Med. 2007; 167: 
1297-304. 
39. Hemila H, Kaprio J, Pietinen P, Albanes D, Heinonen OP. Vitamin 
C and other compounds in vitamin C rich food in relation to risk of 
tuberculosis in male smokers. Am. J. Epidemiol. 1999; 150: 632-41. 
40. Edwards LB, Livesay VT, Acquaviva FA, Palmer CE. Height, 
weight, tuberculous infection, and tuberculous disease. 1971; 22: 
106-12. 
41. Palmer CE, Jablon S, Edwards PQ. Tuberculosis morbidity of 
young men in relation to tuberculin sensitivity and body build. 
1957; 76: 517-39. 
42. Tverdal A. Body mass index and incidence of tuberculosis. Eur. J. 
Respir. Dis. 1986; 69: 355-62. 
43. Maas JJ, Dukers N, Krol A, van Ameijden EJ, van Leeuwen R, 
Roos MT, et al. Body mass index course in asymptomatic HIV-
infected homosexual men and the predictive value of a decrease of 
body mass index for progression to AIDS. JAIDS. 1998; 19: 254-9. 
44. Womack J, Tien PC, Feldman J, Shin JH, Fennie K, Anastos K, et 
al. Obesity and immune cell counts in women. Metabolism. 2007; 
56: 998-1004. 
45. Kassu A, Tsegaye A, Petros B, Wolday D, Hailu E, Tilahun T, et al. 
Distribution of lymphocyte subsets in healthy human 
immunodeficiency virus-negative adult Ethiopians from two 
geographic locales. Clin. Diagn. Lab. Immunol. 2001; 8: 1171-6. 
46. Kassu A, Tsegaye A, Wolday D, Petros B, Aklilu M, Sanders EJ, et 
al. Role of incidental and/or cured intestinal parasitic infections on 
profile of CD4+ and CD8+ T cell subsets and activation status in 
HIV-1 infected and uninfected adult Ethiopians. Clin Exp Immunol. 
2003; 132: 113-9. 
47. Levin A, Brubaker G, Shao JS, Kumby D, O'Brien TR, Goedert JJ, 
et al. Determination of T-lymphocyte subsets on site in rural 
Tanzania: results in HIV-1 infected and non-infected individuals. 
Int. J. STD AIDS. 1996; 7: 288-91. 
48. Urassa W, Bakari M, Sandstrom E, Swai A, Pallangyo K, Mbena E, 
et al. Rate of decline of absolute number and percentage of CD4 T 
lymphocytes among HIV-1-infected adults in Dar es Salaam, 
Tanzania. AIDS. 2004; 18: 433-8. 
49. Bussmann H, Wester CW, Masupu KV, Peter T, Gaolekwe SM, 
Kim S, et al. Low CD4+ T-lymphocyte values in human 
immunodeficiency virus-negative adults in Botswana. Clin. Diagn. 
Lab. Immunol. 2004; 11: 930-5. 
50. Lugada ES, Mermin J, Kaharuza F, Ulvestad E, Were W, Langeland 
N, et al. Population-based hematologic and immunologic reference 
values for a healthy Ugandan population. Clin. Diagn. Lab. 
Immunol. 2004; 11: 29-34. 
51. Irwin M. Low CD4+ T-cell counts: A Variety of causes and their 
implications to HIV and AIDS.  2001  Accessed 25 July 2012;  
Available at: http://healtoronto.com/irwincd4pr.html. 
52. CASCADE Collaboration. Time from HIV-1 seroconversion to 
AIDS and death before widespread use of highly-active anti-
retroviral therapy. A collaborative analysis. Lancet. 2000; 355: 
1131-7. 
53. Williams BG, Korenromp EL, Gouws E, Dye C. The rate of decline 
of CD4 T-cells in people infected with HIV. arXiv  2009; Available 
from: http://arxiv.org/abs/0908. 1556 
54. Fraser C, Ferguson NM, de Wolf F, Anderson RM. The role of 
antigenic stimulation and cytotoxic T cell activity in regulating the 
long-term immunopathogenesis of HIV: mechanisms and clinical 
implications. Proc. R. Soc. London, Ser. B. 2001; 268: 2085-95. 
55. Marconi VC, Grandits GA, Weintrob AC, Chun H, Landrum ML, 
Ganesan A, et al. Outcomes of highly active antiretroviral therapy in 
the context of universal access to healthcare: the U.S. Military HIV 
Natural History Study. AIDS Res Ther. 2010; 7: 14. 
56. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun 
SC, et al. Low-level viremia persists for at least 7 years in patients 
on suppressive antiretroviral therapy. Proc. Nat. Acad. Sc. USA. 
2008; 105: 3879-84. 
57. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, 
Wensing AM. Virological follow-up of adult patients in 
antiretroviral treatment programmes in sub-Saharan Africa: a 
systematic review. Lancet Infect. Dis. 2010; 10: 155-66. 
58. Gras L, van Sighem A, Bezemer D, Smit C, Wit F, de Wolf F. 
Lower mortality and earlier start of combination antiretroviral 
therapy in patients tested repeatedly for HIV than in those with a 
positive first test. AIDS. 2011; 25: 813-8. 
59. De Beaudrap P, Etard J-F, Diouf A, Ndiaye I, Gueye NF, Gueye 
PM, et al. Modeling CD4+ Cell Count Increase Over a Six-Year 
Period in HIV-1-Infected Patients on Highly Active Antiretroviral 
Therapy in Senegal. Am J Trop Med Hyg. 2009; 80: 1047-53. 
60. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, et 
al. Antiretroviral Therapy for Prevention of Tuberculosis in Adults 
with HIV: A Systematic Review and Meta-Analysis. PLoS Med. 
2012; 9: e1001270. 
61. WHO 2008. Global Tuberculosis Control: Surveillance, Planning, 
Financing. Geneva: World Health Organization. 
 
 
